“Eleven clinical trials that will shape medicine in 2026” – BriaCell Phase 3 Trial Featured in Nature Medicine

About this update from Briacell Therapeutics Corp

[{"type":"image","alt":"BriaCell Therapeutics Corp.","displaySize":"","headline":null,"caption":"BriaCell Therapeutics Corp.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":263,"url":"https://media.zenfs.com/en/globenewswire.com/c0f690ec91d7c396d79b761df6835fd7"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/VF.3uZP0Y9S.3O0ulWOxbQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTM2ODtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/c0f690ec91d7c396d79b761df6835fd7","width":300,"height":263}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Nature Medicine asked leading researchers to name their top clinical trial for 2026, from long-awaited vaccines for infectious diseases to new treatments for advanced cancers and long COVID","length":189,"tagName":"p"}]},{"val":[{"type":"text","content":"BriaCell’s Phase 3 clinical trial in metastatic breast cancer featured as “clinical trial to watch in 2026”","length":107,"tagName":"p"}]},{"val":[{"type":"text","content":"BriaCell anticipates reporting top line data as early as H1-2026","length":64,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":360,"olType":false},{"type":"text","content":"PHILADELPHIA and VANCOUVER, British Columbia, Dec. 18, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, is pleased to announce its Phase 3 Bria-IMT™ clinical trial in metastatic breast cancer has been prominently and independently featured in the Nature Medicine Year In Review’s publication, “Eleven clinical trials that will shape medicine in 2026”1, linked here.","length":531,"tagName":"p"},{"type":"text","content":"As quoted in the Nature Medicine feature, Dr. Sara A. Hurvitz, MD, FACP, stated: “The BRIA-ABC trial is an exciting study focused on people living with metastatic breast cancer. Even though cancer care has come a long way, metastatic breast cancer is still rarely curable, and only a small fraction of patients benefit long-term from current immunotherapy or targeted treatments. That is why this trial was designed — to see if a new cell-based immunotherapy, called Bria-IMT, can actually improve outcomes for people who have already gone through many prior treatments.”","length":571,"tagN...

More updates from Briacell Therapeutics Corp